FDA Enforcement Actions on GLP-1 Medications: A Patient's Guide

The FDA's relationship with the GLP-1 market is complex. As regulator, it both approved brand-name semaglutide and tirzepatide and oversees the compounding pharmacies that produce affordable alternatives. Its enforcement actions have targeted bad actors in the compounding space while the legality of properly conducted compounding remains intact.

Types of FDA Enforcement Actions

Notable Warning Letters

The FDA has issued warning letters to compounding facilities for several categories of violations. These include producing medications without valid prescriptions, failing to meet USP compounding standards, using unapproved or contaminated bulk ingredients, making false claims about medication safety or efficacy, and operating without proper state or federal registration. Importantly, these actions target specific facilities for specific violations, not the practice of GLP-1 compounding generally.

The Drug Shortage Question

The FDA's drug shortage designations are central to GLP-1 compounding access. When semaglutide or tirzepatide is listed on the FDA drug shortage list, compounding pharmacies have clearer legal authority to produce these medications. The shortage designation has been contested by brand manufacturers who argue supply is adequate, while patients and compounders point to affordability as a key component of true access.

The distinction between supply shortage and access shortage is important. A drug may be physically available at brand-name prices while remaining practically inaccessible to millions who cannot afford $1,000+ per month. The legal and regulatory system is still working through how affordability relates to shortage designation.

The Salt Form Controversy

The FDA has raised concerns about different salt forms of semaglutide used in compounding. Brand-name Ozempic uses semaglutide base, while some compounding pharmacies have used semaglutide sodium. The FDA has questioned whether these are pharmacologically equivalent. Reputable compounding pharmacies have responded by sourcing semaglutide base or by providing documentation supporting the therapeutic equivalence of their formulations.

Counterfeit Product Warnings

The FDA has issued multiple warnings about counterfeit GLP-1 products, particularly those sold online from foreign sources. These products may contain incorrect doses, contaminated ingredients, or no active ingredient at all. Protect yourself by only obtaining GLP-1 medications through licensed US providers with transparent pharmacy partnerships, never from foreign websites or social media sellers.

Choosing a Safe, Compliant Provider

The Bottom Line

FDA enforcement protects patients by targeting bad actors, not by prohibiting legitimate compounding. Choose providers like Trimi that work with compliant, licensed pharmacies, and you can access affordable GLP-1 medications with confidence in their safety and quality.